TECHNOLOGY

YNIOS Pharma is a biotech start-up, aiming to develop new oral and parenteral treatments to treat pathologies involving inflammation and restore homeostasis using a proprietary ionic compound that targets innate immune pathways.

At this stage, the company is committed to validating proof of concepts to support the preclinical development of multiple pathologies linked to acute systemic inflammatory responses and chronic inflammation. These pathologies are sepsis first, acute ischemic vascular accident, acute myocardial infarction, SARS, pancreatitis, major surgery, trauma and burns, as well as degenerative diseases with an inflammatory component such as Charcot-Marie-Tooth Disease (CMT).

PRELIMINARY TESTS

Preliminary in vitro tests in Wistar rats confirmed the protective effect of the ionic compound TA64 in a model mimicking ischemic stroke with oxygen and glucose deprivation for 2 hours, followed by oxygen reperfusion and glucose, and YNIOS PHARMA’s ionic compound for 24 hours.

Compound TA6415 provided significant cell death protection by reducing cortical neuron death from 51% to only 5%.

Preliminary in vitro tests on primary cortical neurons of Wistar rats have confirmed the protective efficacy of the ionic compound TA64 incubated 1 hour before intoxication with glutamate (40µM) for 20 minutes of incubation. The improvement of survival rate of neurons was significant: 90% versus 42% with placebo treatment.

Preliminary in vitro tests on sensory neurons of Wistar rats (DRG) confirmed the protective efficacy of the ionic compound TA64 incubated 2 hours before the lesion with 12µM cisplatin for 6 hours. Compound TA64 significantly reduced the release of TNF-α by sensory neurons.